Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Stay on top of what’s happening at JPM. BioSpace is covering all the key announcements all week.
The FDA approved Eisai and Biogen’s lecanemab (Leqembi) Friday afternoon. It is the second anti-amyloid antibody to be approved for Alzheimer’s disease in two years.
Starting a new job often comes with a laundry list of tasks. Learn how to prepare and protect your finances before starting a new job, including what to do about your 401k, stocks, health insurance and more.
PCN-101, a ketamine-based candidate for treatment-resistant depression being developed by Atai’s Perception Neuroscience, fell short in a Phase II trial.
Thursday, Fate Therapeutics announced it terminated the 2020 collaboration agreement with Johnson & Johnson’s biopharma subsidiary Janssen.
Intellia Therapeutics released its strategic priorities for 2023-2024 Thursday, with a heavy emphasis on advancing its lead asset NTLA-2001 as a potential functional cure therapy for ATTR amyloidosis.
Graphite Bio announced it is voluntarily pausing the Phase I/II study of its lead candidate nula-cel in sickle cell disease.
Moderna and CytomX ink a cancer partnership.
In another early high-value deal, Amgen inked a licensing agreement with Synaffix for the development of next-generation antibody-drug conjugates.
BioSpace’s exclusive Hotbed Maps highlights nine different regions to watch across the U.S. The maps, made in vibrant color for BioSpace showcases a one-of-a-kind glance at some of 2023’s headline-making companies.
NovoCure’s novel cancer-fighting platform hits the mark in non-small cell lung cancer.
Metagenomi announced a Series B extension financing round led by Moderna, Leaps by Bayer and several others.